AC Immune, a neurogenerative diseases biopharma company, appointed Madiha Derouazi as chief scientific officer and promoted Christopher Roberts to chief financial officer from interim CFO. Dr Derouazi brings scientific and business development experience to AC Immune from her previous positions as CEO ofSperansa Therapeutics, leading the development of a platform of prophylactic vaccines, and as founder and CEO of AMAL Therapeutics in 2012, developing a new generation of therapeutic cancer vaccines.
She led AMAL’s acquisition by Boehringer Ingelheim for EUR 425 million in 2019. Dr Derouazi holds a PhD in cellular biotechnology from the Swiss Federal Institute of Technology (EPFL) in Lausanne. Mr Roberts holds a bachelor of science in accounting, auditing and finance from Lancaster University, UK and is a UK chartered accountant. AC Immune’s platform currently features 10 therapeutic and three diagnostic candidates, of which five are in Phase 2 clinical trials and one in Phase 3.
AC Immune announced the appointments on December 1, 2023
Copyright 2024 Evernow Publishing Ltd.